SuZhou LaiTeou
- Country:
China (Mainland) - Year Established: 2013
- Business type: Trading Company
- Contact Details | Similar Products
You May Like:
-
Diethyl malonate CAS: 1 CAS No.: 105-53-3
USD $1.00-1.00 / Kilogram
-
Factory supply Glibenclamide CAS No.: 10238-21-8
USD $10.00-10.00 / Gram
-
high purity Mavacamten CAS 1 CAS No.: 1642288-47-8
USD $20.00-40.00 / Kilogram
-
( R)-3-(Methylamino)-1-pheny CAS No.: 115290-81-8
USD $3.00-10.00 / Kilogram
-
4-Fluorobenzeneboronic acid CAS No.: 1765-93-1
USD $9.00-99.00 / Kilogram
-
gamma-Cyclodextrin CAS 17465 CAS No.: 17465-86-0
USD $9.00-99.00 / Kilogram
-
Ammonium paratungstate CAS CAS No.: 11120-25-5
USD $9.00-99.00 / Kilogram
-
SODIUM PERCHLORATE MONOHYDRA CAS No.: 7791-07-3
USD $9.00-99.00 / Kilogram
-
4-CHLORO-3-HYDROXYPYRIDINE C CAS No.: 96630-88-5
USD $9.00-99.00 / Kilogram
ALT-711 Alagebrium chloride 341028-37-3 CAS NO.341028-37-3
- FOB Price:
- USD 1.00-1.00 /Gram Get Latest Price
- Min.Order Quantity:
- 1 Gram
- Purity:
- 99%
- Port:
- china
- Payment Terms:
- L/C,D/A,D/P,T/T,MoneyGram,Other
Keywords
- 341028-37-3
- ALT-711
- Alagebrium chloride
Quick Details
- ProName: ALT-711 Alagebrium chloride 341028-...
- CasNo: 341028-37-3
- Molecular Formula: C13H14ClNOS
- Appearance: white powder
- Application: pharmaceutical
- DeliveryTime: stocking
- PackAge: confirms to customer
- Port: china
- ProductionCapacity: 1 Kilogram/Day
- Purity: 99%
- Storage: shade
- Transportation: confirms to customer
- LimitNum: 1 Gram
- Moisture Content: 0.5%
- Impurity: 0.1%
Superiority
alagebrium (formerly known as alt-711) was a drug candidate developed by alteon corporation. it was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts(ages), thereby reversing one of the main mechanisms of aging.[1] through this effect alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking.[2][3][4] alagebrium has proven effective in reducing systolic blood pressure[5]and providing therapeutic benefit for patients with diastolic heart failure.[6]
Details
alagebrium (formerly known as alt-711) was a drug candidate developed by alteon corporation. it was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts(ages), thereby reversing one of the main mechanisms of aging.[1] through this effect alagebrium is designed to reverse the stiffening of blood vessel walls that contributes to hypertension and cardiovascular disease, as well as many other forms of degradation associated with protein crosslinking.[2][3][4] alagebrium has proven effective in reducing systolic blood pressure[5]and providing therapeutic benefit for patients with diastolic heart failure.[6]